ArticleMolecular psychiatry2019
The importance of buprenorphine research in the opioid crisis.
Article in Molecular psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Trial
- Implementation of screening and assessment tools for diagnosing opioid use disorder: A systematic review.Drug and alcohol dependence reports · 2025Review
- Measuring network dynamics of opioid overdose deaths in the United States.Scientific reports · 2024Article
- Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study.Pharmacotherapy · 2024Article
- Stability and Degradation of Opioids in River Water.ACS omega · 2024Article
- Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use.International journal of environmental research and public health · 2022Article
- Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.World journal of psychiatry · 2021Review
- Treatment with buprenorphine prior to EcoHIV infection of mice prevents the development of neurocognitive impairment.Journal of leukocyte biology · 2021Article
- Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review.Frontiers in pharmacology · 2021Review
- The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.Translational psychiatry · 2019Review
- Medications for Opioid Use Disorder: A Guide for Physicians.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the urgency to treat patients more effectively for opioid use disorder in the midst of the opioid epidemic, a key area for precision medicine is to improve individualized medication-assisted treatment for opioid use disorder. The expansion of medication-assisted treatment is a key to reducing illicit opioid use, preventing opioid overdose deaths, and reducing the comorbidities and societal impacts of opioid use disorder. The most common medication for opioid use disorder will soon be buprenorphine. Research to date shows the successful impact of buprenorphine treatment, including the pharmacogenomics of buprenorphine response and treatment efficacy. Buprenorphine is also a promising treatment for depression and anxiety, and neonatal opioid withdrawal syndrome (NOWS). However, the rates of success with medication-assisted treatment for opioid use disorder, particularly at the beginning of treatment, still show many individuals relapsing to illicit opioid use. With the scope of the opioid crisis, there is an urgent need for expansion of buprenorphine treatment research to provide critical information for improving outcomes of opioid use disorder. Implementing the best strategies for opioid use disorder treatment is of dire urgency and will save lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.